glp-1 cardiovascular outcomes 2025 news Risks after Discontinuation Glucagon-like peptide 1 receptor agonists:

Clinically, it hopes for safer grafting and longer-lasting volume

GLP-1 RAs significantly reduce the risk of MACE

You need not spend hours at a gym

Some researchers follow even more conservative titration using microdosing approaches

On November 2023, the United States Food and Drug Administration (FDA) has approved Eli Lilly and Company s Zepbound (tirzepatide) injection, the first and only obesity medication to activate both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors

Within 3 d after the switch, an MMTT suggested recovery of basal and postprandial insulin secretion (Table 1b)